Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$4.25
EPS est.
$4.09
EPS surprise
+3.81%
1-day move
-0.13%
Labcorp's earnings report showed a positive surprise in EPS, indicating stronger-than-expected profitability. However, the stock reacted slightly negatively, declining by 0.13%. The lack of revenue data and management commentary may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.25 | $4.12 | +3.81% |
| Revenue | N/A | $3.5B | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Labcorp Holdings Inc. is a leading health care company that provides laboratory services and diagnostic solutions. With a market cap of $21 billion, it plays a crucial role in the health care sector, particularly as demand for testing and diagnostics continues to grow.
Last quarter
In the last quarter, Labcorp reported an EPS of $4.07, exceeding expectations by nearly 3%. However, the stock experienced a slight decline the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+2.87%
Avg 1-day reaction
+1.25%
Analysts expect Labcorp to report solid earnings this quarter, with a consensus EPS of $4.12. Investors are particularly focused on revenue growth and any potential guidance from management.
Bull case
If Labcorp exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its services, leading to a positive stock reaction.
Bear case
Conversely, if the company misses EPS estimates or provides weak guidance, it could raise concerns about demand and profitability, negatively impacting the stock.
Key metrics to watch
EPS
$4.12Earnings per share is a key indicator of profitability and performance, which investors closely watch.
Revenue
$3.5BRevenue figures provide insight into the company's overall sales performance and market demand.
The print will turn on these.
Q1
Will Labcorp's EPS exceed the consensus estimate of $4.12?
A beat on EPS could indicate stronger-than-expected profitability and boost investor confidence.
Q2
What guidance will management provide regarding revenue growth?
Management's outlook on revenue will be crucial for assessing future performance and market demand.
Est. EPS
$1.21
Est. Rev
$34.9B
Impl. Move
±5.2%
Why consensus could be wrong
The consensus may underestimate Labcorp's ability to leverage its diagnostic services amid rising health care demand, which could lead to stronger revenue growth than anticipated.
Supporting evidence
The company's consistent EPS beats suggest a stronger operational performance than analysts expect.
Options pricing indicates a significant potential move, suggesting that the market is bracing for volatility.
Key risk
If revenue growth exceeds expectations, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter, the focus is on whether Labcorp can maintain its earnings momentum amid changing market conditions.
Bull confirmed if
An EPS of $4.20 or higher would confirm the bull case, indicating strong profitability.
Bear confirmed if
An EPS below $4.00 would support the bear case, raising concerns about demand.
What the market is pricing for the move.
Implied Move
±4.3%
Historical Avg
±3.5%
The options market is pricing in a potential move of around 4.3%, indicating uncertainty about the earnings report.
Options are pricing ±4.3% while LH has averaged ±3.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
23.8%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 7 of 23 (30%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
101.81%
of float
Insider
0.35%
of float
Holders
1,441
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
6,574,261 sh · $2.1B
8.11%
2.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Labcorp beats expectations, history suggests the stock could rise by around 1.39%, confirming a positive trend.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical data suggesting a potential drop of around 4.74%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
4
0 buys·4 sells
Members
1
House only
Est. Notional
$103,004.00–$295,000.00
disclosed dollar ranges
Most Active Members
4 trades
The lines on the call that would change the story.
Vanguard Capital Management LLC
5,362,254 sh · $1.7B
6.61%
-0.3%
Victory Capital Management Inc.
4,837,573 sh · $1.5B
5.96%
4.6%
State Street Corporation
3,907,656 sh · $1.2B
4.82%
1.1%
Vanguard Portfolio Management LLC
3,678,798 sh · $1.1B
4.54%
-0.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Aug 25, 2026 · disclosed Sep 9, 2026
$100,001.00–$250,000.00
Traded Aug 7, 2026 · disclosed Sep 9, 2026
$1,001.00–$15,000.00
Traded Aug 6, 2026 · disclosed Sep 9, 2026
$1,001.00–$15,000.00
Traded Aug 5, 2026 · disclosed Sep 9, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.